Skip to main content

Table 1 Demographics and clinical data of patients with unresectable pancreatic cancer according to the study group

From: Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis

  Group 1 Group 2 P value
n (%) 86 (53.75%) 74 (46.25%)  
Age at diagnosis, median (range), years 71.5 (43–100) 69.5 (28–90) 0.470c
Gender (M/F) 52/34 40/34 0.427
Tumor Stage (locally advanced/metastatic) 16/70 18/56 0.440
Tumor location (head/body/tail) 46/33/7 47/21/6 0.396
Tumor size, mean ± SD (cm) 4.5 ± 1.5 4.1 ± 1.5 0.828d
Patients with CA 19–9 > 1000 U/mL at diagnosisa 40 (55.5%) 33 (47.8%) 0.401
Weight loss > 10% BW at diagnosis, n (%) 47 (54.7%) 48 (64.9%) 0.220
Patients receiving palliative chemotherapy, n (%) 40 (46.5%) 53 (71.6%) 0.001
Number of chemotherapy cycles, median (range)b 3 (0.3–20) 4 (1–40) 0.004c
Survival, median (range), days 95.0 (33–768) 189 (31–997) < 0.001c
Patients receiving PERT, n (%) 0 (0%) 49 (66.2%) < 0.001
  1. aAfter biliary drainage in patients with obstructive jaundice (data available in 88.1% of patients)
  2. bPatients receiving chemotherapy (n = 93)
  3. cMann–Whitney U test
  4. dStudent-t test